Forskning ved Københavns Universitet - Københavns Universitet

Forside

Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

Aminosalicylates and colorectal cancer in IBD : a not-so bitter pill to swallow. / Ryan, B M; Russel, M G V M; Langholz, E; Stockbrugger, R W.

I: The American Journal of Gastroenterology, Bind 98, Nr. 8, 08.2003, s. 1682-7.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Ryan, BM, Russel, MGVM, Langholz, E & Stockbrugger, RW 2003, 'Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow', The American Journal of Gastroenterology, bind 98, nr. 8, s. 1682-7. https://doi.org/10.1111/j.1572-0241.2003.07599.x

APA

Ryan, B. M., Russel, M. G. V. M., Langholz, E., & Stockbrugger, R. W. (2003). Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. The American Journal of Gastroenterology, 98(8), 1682-7. https://doi.org/10.1111/j.1572-0241.2003.07599.x

Vancouver

Ryan BM, Russel MGVM, Langholz E, Stockbrugger RW. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. The American Journal of Gastroenterology. 2003 aug;98(8):1682-7. https://doi.org/10.1111/j.1572-0241.2003.07599.x

Author

Ryan, B M ; Russel, M G V M ; Langholz, E ; Stockbrugger, R W. / Aminosalicylates and colorectal cancer in IBD : a not-so bitter pill to swallow. I: The American Journal of Gastroenterology. 2003 ; Bind 98, Nr. 8. s. 1682-7.

Bibtex

@article{7fe3f864bb034e88b15e57aad3f0bda1,
title = "Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow",
abstract = "Inflammatory bowel disease (IBD) is associated with an increased risk of developing intestinal cancer at sites of chronic inflammation. Aminosalicylates, including both sulfasalazine and mesalamine, are the most commonly prescribed anti-inflammatory agents prescribed in IBD. On balance, the body of literature to date suggests that aminosalicylates confer some protection against the development of colonic neoplasia in patients with IBD and in a variety of models, including in the noninflamed gut. This latter observation implies that aminosalicylates may be of chemopreventive value in normal as well as IBD individuals. The current review examines and gives an overview of the evidence from a variety of sources, including epidemiological, in vivo and in vitro studies that have investigated the potential anticancer effects of aminosalicylates.",
keywords = "Aminosalicylic Acids/therapeutic use, Animals, Anti-Inflammatory Agents, Non-Steroidal/therapeutic use, Anticarcinogenic Agents/therapeutic use, Colorectal Neoplasms/etiology, Evaluation Studies as Topic, Humans, Inflammatory Bowel Diseases/complications",
author = "Ryan, {B M} and Russel, {M G V M} and E Langholz and Stockbrugger, {R W}",
year = "2003",
month = aug,
doi = "10.1111/j.1572-0241.2003.07599.x",
language = "English",
volume = "98",
pages = "1682--7",
journal = "The American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "nature publishing group",
number = "8",

}

RIS

TY - JOUR

T1 - Aminosalicylates and colorectal cancer in IBD

T2 - a not-so bitter pill to swallow

AU - Ryan, B M

AU - Russel, M G V M

AU - Langholz, E

AU - Stockbrugger, R W

PY - 2003/8

Y1 - 2003/8

N2 - Inflammatory bowel disease (IBD) is associated with an increased risk of developing intestinal cancer at sites of chronic inflammation. Aminosalicylates, including both sulfasalazine and mesalamine, are the most commonly prescribed anti-inflammatory agents prescribed in IBD. On balance, the body of literature to date suggests that aminosalicylates confer some protection against the development of colonic neoplasia in patients with IBD and in a variety of models, including in the noninflamed gut. This latter observation implies that aminosalicylates may be of chemopreventive value in normal as well as IBD individuals. The current review examines and gives an overview of the evidence from a variety of sources, including epidemiological, in vivo and in vitro studies that have investigated the potential anticancer effects of aminosalicylates.

AB - Inflammatory bowel disease (IBD) is associated with an increased risk of developing intestinal cancer at sites of chronic inflammation. Aminosalicylates, including both sulfasalazine and mesalamine, are the most commonly prescribed anti-inflammatory agents prescribed in IBD. On balance, the body of literature to date suggests that aminosalicylates confer some protection against the development of colonic neoplasia in patients with IBD and in a variety of models, including in the noninflamed gut. This latter observation implies that aminosalicylates may be of chemopreventive value in normal as well as IBD individuals. The current review examines and gives an overview of the evidence from a variety of sources, including epidemiological, in vivo and in vitro studies that have investigated the potential anticancer effects of aminosalicylates.

KW - Aminosalicylic Acids/therapeutic use

KW - Animals

KW - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use

KW - Anticarcinogenic Agents/therapeutic use

KW - Colorectal Neoplasms/etiology

KW - Evaluation Studies as Topic

KW - Humans

KW - Inflammatory Bowel Diseases/complications

U2 - 10.1111/j.1572-0241.2003.07599.x

DO - 10.1111/j.1572-0241.2003.07599.x

M3 - Review

C2 - 12907319

VL - 98

SP - 1682

EP - 1687

JO - The American Journal of Gastroenterology

JF - The American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -

ID: 219530584